INmune Bio Inc (NAS:INMB)

Q3 2025 INmune Bio Inc Earnings Call Transcript

Oct 30, 2025 / 08:30 PM GMT

Release Date Price: $1.73 (-4.95%)

Transcript 8-K10-Q

Key Points

Positve

INmune Bio Inc (INMB) is preparing for marketing approval submissions for its Chordstrom MSC platform in both the UK and the US, indicating progress in regulatory pathways.
The company has completed a phase 2 trial for its Alzheimer's drug, XPro, and is pursuing an accelerated regulatory pathway with the FDA.
INmune Bio Inc (INMB) has successfully completed a phase 2 trial of Incommune in prostate cancer, meeting primary and two secondary endpoints.
The company has reduced its net loss significantly from $12.1 million in Q3 2024 to $6.5 million in Q3 2025, indicating improved financial management.
INmune Bio Inc (INMB) has a strong cash position with $27.7 million in cash and cash equivalents, sufficient to fund operations into Q4 2026.

Negative

The company is facing delays in its end of phase 2 meeting with the FDA for XPro, which was initially expected by the end of 2025 but is now anticipated in Q1 2026.
There is uncertainty regarding the regulatory approval timeline for Chordstrom in the US, with expectations to hear back from the FDA by mid-2027 or later.
INmune Bio Inc (INMB) is still in the process of gathering comprehensive data for potential partnerships, indicating that significant work remains before serious discussions can occur.
The company faces competition from existing gene therapies for RDEB, which are already approved in the US, potentially impacting market positioning.
Despite progress, the company acknowledges the challenges inherent in Alzheimer's drug development, which could affect the future success of XPro.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INMB.OQ - INmune Bio Inc
Q3 2025 INmune Bio Inc Earnings Call
Oct 30, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
To all locations on hold, we do appreciate your patience and please continue to send.

Please stand by. Your program is about to begin.

Greetings and welcome to the Immune bio Third quarter, 2025 earnings call.

At this time, all participants are in a listen-only mode.

Later you will have the opportunity to ask questions during the question-and-answer session.

You may register to ask questions by pressing the star and one on your telephone keypad.

You may withdraw yourself from the queue by pressing 2.

As a reminder, this conference is being recorded.

A transcript will follow within 24 hours of this conference call.

At this time, it is my pleasure to introduce

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.